Semaglutide for the Treatment of Cannabis Use Disorder

The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder. The main questions it aims to answer are: 1. Does semaglutide effect reactivity to cannabis-related cues? 2. Does semaglutide safely reduce the frequency of cannabis use? Participants will complete five in-person study visits over 9 weeks, which will include interviews, questionnaires, and collection of biological samples for laboratory testing. fMRI scans will be completed at two visits. All participants will receive weekly injections of 0.25-0.5 mg semaglutide across 8 weeks.

Inclusion Criteria: * Adults aged 18-60 years, inclusive; * Use cannabis daily or near daily and have been using cannabis consistently for at least the past year, by self-report; * Diagnosed with moderate to severe DSM-5 cannabis use disorder * Access to a mobile device to complete daily surveys * Desire to quit or reduce cannabis consumption * Be able to read, speak, and understand the English language. English can be a second language provided that the subject understands all the questions used in the assessment measures. Exclusion Criteria: * Active psychosis, active suicidality (current suicidal ideation with specific plan or intent) or homicidality, suicide attempt or psychiatric hospitalization in the past year, or any psychiatric condition that may impair ability to provide informed consent. * Any current or lifetime diagnosis of eating disorders including anorexia, bulimia, or binge eating; * Any current substance use disorder other than cannabis or mild alcohol use disorder; * BMI \